UPFRONT BRIEFING
The FDA spent Monday on the fine print of obesity's biggest franchises: all 12 approved GLP-1s pick up a Warnings and Precautions line on NAION, a rare optic-nerve stroke. The math is 6.4 versus 3.8 cases per 100,000 patient-years: rare enough that BMO isn't sweating Lilly or Novo, real enough that every prescriber conversation just got one sentence longer.
Bayer, meanwhile, got the first Factor XIa inhibitor over the line with Sunharbo, and Ionis found out how fast a launch can halve: Tryngolza's 2026 guide went from $100–110M to about $50M. BIO-Europe wraps in Cologne tomorrow, and the BIO lobby used the week to pitch Washington a seven-point plan to stay ahead of China.
TAPE ACTION

Healthcare lagged a broad rally, with XLV +1.9% vs the S&P 500 +2.3%, while higher-beta biotech kept pace: XBI +3.1%, NBI +2.7%, BBC +4.6%. Single names moved on company news: Vir +11.8% on Sunday's ECLIPSE 1 hepatitis delta data, Ionis (21.4%) on its 07:00 ET Tryngolza guidance cut.
The S&P had its best day since 8 April after Trump called renewed Iran strikes "highly unlikely" and Brent fell (5.9%) to $92.57; AMD +13.3% on an Oppenheimer upgrade lifted chips (SOXX +7.5%) even as Nvidia fell (4.3%) on a board probe of Jensen Huang. NDX +3.4%, RUT +3.1%, Dow +2.15%; VIX (22%) to 19.92; 10Y +2bp to 4.88% ahead of today's 8:30 ET October CPI.
THE BIG 3
1️⃣ — FDA orders GLP-1 label updates for rare eye disease risk
The FDA ordered all 12 approved GLP-1 receptor agonists, including Novo's Wegovy and Ozempic and Lilly's Zepbound, Mounjaro and oral Foundayo, to add a potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) to their labels. FDA's meta-analysis of 126 trials (78,217 GLP-1 patients) found 6.4 vs 3.8 probable cases per 100,000 patient-years against comparators.
Why it matters: This is a Warnings and Precautions entry, not a boxed warning or an indication restriction, so the commercial cost is friction rather than lost scripts. The signal is thin: 15 probable events across 126 trials, and FDA's own real-world study found no excess versus SGLT-2 inhibitors, only versus DPP-4s. BMO sees limited risk to Lilly and Novo, whose GLP-1 franchises each did roughly $36B in 2025, and both stocks rose Monday. The sharper exposure is legal: the 2024 JAMA Ophthalmology semaglutide paper already seeded vision-loss suits, and a class label hands plaintiffs a regulatory hook. Orals and next-wave entrants inherit the language at launch.
Source: Endpoints
2️⃣ — Bayer wins FDA approval for Sunharbo in stroke prevention
The FDA approved Bayer's Sunharbo (asundexian), a once-daily oral Factor XIa inhibitor taken with antiplatelet therapy, to cut recurrent stroke risk in adults after a non-cardioembolic ischemic stroke or high-risk TIA; it is the first FXIa drug cleared in the U.S. In OCEANIC-STROKE (>12,000 patients) it cut ischemic stroke 26% vs placebo with similar major bleeding. List price is $748.50 a month.
Why it matters: Bayer needed this one. Xarelto's ex-U.S. sales fell almost 43% to €738M in the first half on generics, and asundexian already stumbled in atrial fibrillation. Stroke is the narrower but cleaner beachhead: a 26% cut in ischemic stroke on top of antiplatelets, without extra major bleeding, is the efficacy-safety split the Factor XIa class was built to deliver. It also sets the bar for BMS and J&J's milvexian, which Leerink models at $2.5B in risk-adjusted 2032 sales after several setbacks, and for Novartis' antibody from its $925M Anthos buy. At $748.50 a month the constraint is access, not demand; Bayer starts with stroke neurologists.
Source: Endpoints
More: STAT; BioPharma Dive
3️⃣ — Ionis halves its Tryngolza forecast as the sHTG launch stalls
Ionis cut 2026 Tryngolza (olezarsen) sales guidance to about $50M from $100–110M after Q3 U.S. net sales of $9M vs ~$21M consensus. Q3 total revenue was $243M and the $875–900M total 2026 revenue guide held. Shares fell 21.4% Monday, wiping out more than $1B of market value.
Why it matters: Tryngolza was meant to be Ionis' first self-launched blockbuster once it moved from ultra-rare FCS into severe hypertriglyceridemia; a $9M quarter says the new treatment paradigm is not converting prescribers on schedule. Management called the ramp "more gradual than anticipated" but held total guidance because Dawnzera ($37M in Q3, $110-120M full-year guide unchanged) and royalties are carrying the year. Arrowhead, whose plozasiran competes in triglyceride lowering, fell 15.3% the same day. With about $1.9B of cash and sefaxersen and ulefnersen filings due in 2027, the balance sheet is not the issue; launch execution now gets priced into every Ionis asset.
Source: STAT
More: Ionis release
EVERYTHING ELSE THAT BROKE
Lilly's Foundayo hit the primary endpoint in Phase 3 ATTAIN-OSA (~712 patients, 52 weeks): breathing interruptions fell up to 44% and up to 32% reached remission or mild disease; an FDA filing is planned by year-end. — STAT
Boehringer and Zealand's survodutide was non-inferior to placebo on MACE in SYNCHRONIZE-CVOT (n=5,530; AHA and The Lancet), but discontinuations ran 19.3–20.8% vs 1.9%. — BioSpace
Zura Bio's tibulizumab missed a Phase 2 hidradenitis suppurativa trial; Zura is ending development there but continuing other studies, and the stock sank. — Fierce Biotech
The Pentagon removed WuXi AppTec from its Section 1260H Chinese military company list to comply with August's court injunction. — Endpoints
BIO rolled out a seven-part "BioAdvance" plan to speed U.S. biotech development and compete with China. — BioPharma Dive
DEAL FLOW
Track the Deals Shaping Biotech
Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.
M&A / BD&L
Third Rock Ventures struck an AI antibody-discovery pact worth up to $2.16B with Chinese biotech Funnel Biosciences; upfront and structure undisclosed. — Endpoints
Kyorin is paying $12M upfront, in a deal worth up to $140M, for Japan rights to Edesa's Phase 3 anti-TLR4 antibody in acute respiratory distress syndrome. — Fierce Biotech
CorMedix will buy substantially all of Heron's assets (Zynrelef, Aponvie, Cinvanti, Sustol) for $145M cash plus 14.6M CRMD shares (~$77.6M), up to $55M in Zynrelef sales milestones and a 5% royalty tier; Heron holder vote, close 1Q27. — Endpoints
PharmaLogic will buy Lantheus' radiopharma CDMO business and Springfield, NJ site into its Agilera unit, with a long-term Lu-177 dotatate supply deal back to Lantheus; terms undisclosed. — PR Newswire
Avanzanite licensed Zemcelpro (UM171 cell therapy) from Cordex/ExCellThera for 32 European countries (EEA, UK, Switzerland) after its conditional EC authorisation: development fees, milestones and royalties, amounts undisclosed. — BioSpace
VC / PRIVATE FINANCINGS
Delix Therapeutics raised a $100M Series C co-led by JJDC and SV Health Investors' Dementia Discovery Fund, joined by RA Capital, Adage, Vestal Point and Hamilton Square; zalsupindole (DLX001) moves into a Phase 2b in recurrent MDD in 1H27. — Endpoints
London's Oyster raised a $60M Series A-2 led by 4BIO Capital with Eli Lilly participating, for tau-targeting protein degraders (preclinical). — BioPharma Dive
IPO / FOLLOW-ON
Windward Bio (WWB) set terms for a ~$204M IPO to fund two respiratory drugs licensed from China (WIN378, WIN027). — Fierce Biotech
ACADEMIC CORNER
Resistance exercise reduced lean mass loss during tirzepatide therapy for obesity in a randomized controlled trial. — Nature Medicine
A Nature Reviews Drug Discovery review mapped the biology and therapeutic prospects of histone lysine demethylases. — Nature RDD
A Nature Reviews Drug Discovery review examined conditional biologics in cancer immunotherapy and their clinical progress. — Nature RDD
In a Phase 2b trial, ANGPTL4 antibody MAR001 significantly lowered fasting triglycerides at 12 weeks. — NEJM
Know someone who'd like this?
Forward it along. It takes ten seconds and means a lot to us.
Today's small print: read the label, then the guidance.
— The BioBucks Team
